ArticleJournal of experimental & clinical cancer research : CR2017
AHNAK suppresses tumour proliferation and invasion by targeting multiple pathways in triple-negative breast cancer.
Article in Journal of experimental & clinical cancer research : CR, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 74 citations in OpenAlex.
- Tumour location and mismatch repair status impact gene expression profiles associated with lymph node metastases in T1 colon cancers.Scientific reports · 2026Article
- CycleMix: Gaussian mixture modeling of the cell cycle.Bioinformatics advances · 2026Article
- Tumor-educated platelet RNA as a diagnostic biomarker for ground-glass opacity-related lung adenocarcinoma.Translational lung cancer research · 2025Article
- Integrating gene mutation spectra from tumors and the general population with gene expression topological networks to identify novel cancer driver genes.Human genetics · 2025Article
- NLRP4 unlocks an NK/macrophages-centered ecosystem to suppress non-small cell lung cancer.Biomarker research · 2025Article
- Circ6834 suppresses non-small cell lung cancer progression by destabilizing ANHAK and regulating miR-873-5p/TXNIP axis.Molecular cancer · 2024Article
- Silencing AHNAK promotes nasopharyngeal carcinoma progression by upregulating the ANXA2 protein.Cellular oncology (Dordrecht, Netherlands) · 2024Article
- Cancer-specific alterations in nuclear matrix proteins determined by multi-omics analyses of ductal carcinomaFrontiers in oncology · 2024Article
- Cooperatively designed aptamer-PROTACs for spatioselective degradation of nucleocytoplasmic shuttling protein for enhanced combinational therapy.Chemical science · 2023Article
- BLCA prognostic model creation and validation based on immune gene-metabolic gene combination.Discover oncology · 2023Article
- Stress granules and hormetic adaptation of cancer.Trends in cancer · 2023Review
- A tRF-5a fragment that regulates radiation resistance of colorectal cancer cells by targeting MKNK1.Journal of cellular and molecular medicine · 2023Article
- Downregulation of AHNAK2 inhibits cell cycle of lung adenocarcinoma cells by interacting with RUVBL1.Thoracic cancer · 2023Article
- Article
- AHNAKs roles in physiology and malignant tumors.Frontiers in oncology · 2023Review
- AHNAK Contributes to Hepatocellular Carcinoma Growth by Interacting with IGF-1R.Molecules (Basel, Switzerland) · 2022Article
- The AHNAK induces increased IL-6 production in CD4+ T cells and serves as a potential diagnostic biomarker for recurrent pregnancy loss.Clinical and experimental immunology · 2022Article
- The Obscure Potential of AHNAK2.Cancers · 2022Review
- DeleteriousFrontiers in oncology · 2022Article
- LncRNA-RMST Functions as a Transcriptional Co-regulator of SOX2 to Regulate miR-1251 in the Progression of Hirschsprung's Disease.Frontiers in pediatrics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAHNAK, also known as desmoyokin, is a giant protein with the molecular size of approximately 700 kDa and exerts diverse functions in different types of cancer.
resultsIn the present study, we demonstrated that AHNAK mRNA levels were down-regulated in 7 out of 8 human breast cancer cell lines, especially in triple - negative breast cancer (TNBC) cell lines. Moreover, in patients with TNBC, the expression of AHNAK gene was inversely correlated with the tumor status (P = 0.015), lymph node status (P < 0.001), lymph node (LN) infiltration (P < 0.001) and TNM stage (P < 0.001). Moreover, down-regulated AHNAK expression was considered an independent prognostic factor associated with the poor survival of patients with TNBC. Overexpression of AHNAK in two TNBC cell lines, MDA-MB-231 and BT549, suppressed the in vitro TNBC cell proliferation and colony formation, and inhibited the in vivo TNBC xenograft growth and lung metastasis. The tumor suppressing effect of AHNAK in TNBC was associated with the AKT/MAPK signaling pathway and Wnt/β-catenin pathway. Consistent results were observed when AHNAK was knockdown in BT20 and MDA-MB-435 cells.
conclusionsTaken together, our results suggest that AHNAK acts as a tumor suppressor that negatively regulates TNBC cell proliferation, TNBC xenograft growth and metastasis via different signaling pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.